Bionor stock skyrockets on unexpected HIV vax results

Norway's Bionor Pharma's stock almost quadrupled on the news that its HIV vaccine Vacc-4x unexpectedly reduced viral load. The trial was designed to test HIV-patients' ability to stay off antiretroviral therapy after having been immunized with Vacc-4x. It missed that endpoint. But researchers found that patients injected with Vacc-4x experienced a drop in levels of the virus; moreover, viral loads never returned to the levels seen before the patients started antiretroviral therapy. Due to the new findings, Bionor has reversed an earlier decision to stop development of the vaccine.

"Patients starting on antiretrovirals see the viral load effectively reduced, but this is dependent on daily treatment, and we know that HIV remains in the reservoirs," said Richard Pollard, the principle investigator in the trial. "A therapeutic HIV vaccine like Vacc-4x reducing the viral load set-point, could have significant implications for future HIV management used in combination with ART. More research is needed to confirm this hypothesis."

- see Bionor's release
- get more from Bloomberg

Suggested Articles

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.